ACS/ASCCP/ASCP guidelines for the early detection of cervical cancer

American Family Physician

Volumn 86, Issue 6, 2012, Pages 501-

  Fontaine, Patricia L ^a   Saslow, Debbie ^b   King, Valerie J ^c  

^a HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AGE; CANCER GRADING; CANCER RISK; CANCER SCREENING; COLPOSCOPY; CYTOLOGY; EARLY DIAGNOSIS; EDITORIAL; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; HYSTERECTOMY; INCIDENCE; NON PROFIT ORGANIZATION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CANCER; VAGINA SMEAR;

EID: 84866465016     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147-172.
2. Moscicki AB, Cox JT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010;14(1):73-80.
3. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. AHRQ publication no. 11-05157-EF-1. Rockville, Md.: Agency for Healthcare Research and Quality; 2011.
4. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice [published correction appears in Lancet Oncol. 2011;12(8):722]. Lancet Oncol. 2011;12(7):663-672.
5. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies [published correction appears in Int J Cancer. 2007;120(11):2525]. Int J Cancer. 2007;120(4):885-891.
6. Castellsagué X, Díaz M, de Sanjosé S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98(5):303-315.
7. Sirovich BE, Welch HG. Cervical cancer screening among women without a cervix. JAMA. 2004;291(24):2990-2993.
8. Good Stewardship Working Group. The "top 5" lists in primary care: meeting the responsibility of professionalism. Arch Intern Med. 2011;171(15):1385-1390.
9. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests [published correction appears in J Low Genit Tract Dis. 2008;12(3):255]. J Low Genit Tract Dis. 2007;11(4):201-222.
10. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135(3):468-475.
11. Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol. 2007;109(6):1325-1331.
12. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005;97(14):1066-1071.
13. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. AHRQ publication no. 11-05156-EF-2. March 2012. http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerrs.htm. Accessed June 11, 2012.
14. Freeman HP, Wingrove BK; Center to Reduce Cancer Health Disparities (U.S.). Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities: An Analysis. Rockville, Md.: National Cancer Institute; 2005.